Assessment of Exercise Intensity in Cardiac Rehabilitation Programmes for Patients With Chronic Heart Failure

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2012 by Eastbourne General Hospital.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by (Responsible Party):
Guy Lloyd, Eastbourne General Hospital
ClinicalTrials.gov Identifier:
NCT01545102
First received: February 29, 2012
Last updated: March 6, 2012
Last verified: March 2012
  Purpose

Cardiac rehabilitation is the ideal comprehensive intervention for patients with chronic heart failure (CHF), since it addresses the complex interplay of medical, psychological and behavioural factors facing these individuals. Structured exercise training within a cardiac rehabilitation programme is firmly recommended for these patients. However, it is questionable whether patients are achieving an adequate dose of exercise to provide optimal benefits. The essential components for setting optimal training include the appropriate mode, duration, frequency and intensity of exercise. UK surveys of cardiac rehabilitation describe the frequency and duration of training, but here is scant information on exercise intensity. However, it is apparent that randomised controlled trials of exercise training use doses more than 4 times greater than in UK current practice. The Eastbourne Exercise Cardiology Research Group has demonstrated that although patients benefit from improved quality of life and submaximal fitness after a hospital outpatient cardiac rehabilitation programme, they do not achieve the increases in important prognostic indicators reported by the majority of exercise training trials.

The critical factor in terms of eliciting a sufficient training effect while minimising risk is the intensity of the exercise performed. It is now widely accepted that the traditional methods of using fixed percentages of maximal heart rate or oxygen uptake to set exercise intensity include serious errors. The European Society of Cardiology recommends that cardiopulmonary exercise testing should be used to provide an objective evaluation of the metabolic demand of exercise. This allows physiologically meaningful reference points to be established for aerobic exercise prescription and is the solution to defining safe and effective training intensities. The next step is to determine whether this information can be transferred to a practical cardiac rehabilitation environment to set and monitor exercise intensity


Condition
Cardiac Failure

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Assessment of Exercise Intensity in Cardiac Rehabilitation Programmes for Patients With Chronic Heart Failure

Resource links provided by NLM:


Further study details as provided by Eastbourne General Hospital:

Primary Outcome Measures:
  • The primary outcome measure is the oxygen uptake(VO2)during exercise [ Time Frame: 13 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Affective responses (e.g. feelings of pleasure/displeasure) [ Time Frame: 13 weeks ] [ Designated as safety issue: No ]
    Questionnaire used to measure affective responses (Feelings Scale, Felt Anxiety Scale and Activation/Deactivation )

  • Weekly physical activity [ Time Frame: 13 weeks ] [ Designated as safety issue: No ]
    Average daily physical activity: Participants' freeliving activity will be classified by ActivPAL into periods spent sitting, standing and walking, and daily energy expenditure will also be estimated from this information.


Estimated Enrollment: 21
Study Start Date: April 2012
Estimated Study Completion Date: April 2013
Estimated Primary Completion Date: April 2013 (Final data collection date for primary outcome measure)
Detailed Description:

Background Heart failure is a chronic, costly and life-threatening disorder that constitutes a significant burden for individuals and the National Health Service [There are 27,000 new cases reported per annum in the UK. Cardiac rehabilitation (CR) is recommended as the ideal comprehensive intervention since it addresses the complex interplay of medical, psychological and behavioural factors facing CHF patients and carers.

Study Aim Primary objective to describe the exercise intensity, defined by oxygen uptake (VO2) in terms of the individual physiological thresholds, in CHF patients undergoing CR according to current guidelines Primary end point: VO2 Secondary objectives Secondary objectives of this study are:-

  1. To measure resting and exercising energy expenditure in order to a) establish the value of 1 MET (resting metabolic rate) for patients with CHF, and b) to establish the MET value (defined as multiples of resting metabolic rate) for exercises performed in CR sessions
  2. To measure affective responses (feeling very bad - feeling very good; levels of energy - tiredness and tension - calmness) to exercise during CR sessions
  3. To measure weekly physical activity level in CHF patients undergoing Phase III and IV CR.

For the secondary analysis the following secondary end points and parameters will be established

  1. MET values, defined as multiples of resting oxygen uptake or resting metabolic rate (1 MET), for different CR exercises
  2. Ratings of affective response on the Feelings Scale (FS) and ratings of perceived activation on the Felt Arousal Scale (FAS).
  3. Average daily activity over 7 day period in terms of steps per day and periods spent sitting, standing and walking
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

21 CHF patients from Heart Failure clinic at Eastbourne District General Hospital

Criteria

Inclusion criteria:

  • Systolic heart failure with resting left ventricular ejection fraction below 40%
  • New York Heart Association (NYHA) class I-III
  • clinically stable for at least 4 weeks on optimised medication dosage according to current guidelines

Exclusion criteria:

  • Acute coronary syndrome within past 6 months
  • Untreated lifethreatening cardiac arrhythmias
  • Acute heart failure (during initial period of haemodynamic instability)
  • Uncontrolled hypertension
  • Advanced atrioventricular block
  • Acute myocarditis or pericarditis
  • Symptomatic aortic stenosis
  • Severe hypertrophic obstructive cardiomyopathy
  • Acute systemic illness Intracardiac thrombus
  • Progressive worsening of exercise tolerance of dyspnoea at rest over previous 35 days
  • Significant ischaemia during low intensity exercise (< 2 METS, < 50W)
  • Uncontrolled diabetes
  • Recent embolism
  • Thrombophlebitis
  • New onset atrial fibrillation/flutter
  • > 1.8 kg increase in body mass over previous 13 days
  • Concurrent, continuous or intermittent dobutamine therapy
  • Decrease in systolic blood pressure with exercise
  • NYHA Functional Class IV
  • Complex ventricular arrhythmia at rest or appearing with exertion
  • Supine resting heart rate > 100 beats/min
  • Patient is participating in a conflicting study, is unable to perform exercise testing
  • Patient lacks the capacity to consent or cannot comply with study requirements
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01545102

Contacts
Contact: Jet van Zalen, MSc, BSc 01323417400 ext 4132 jet.vanzalen@esht.nhs.uk

Locations
United Kingdom
Eastbourne General Hospital Not yet recruiting
Eastbourne, East Sussex, United Kingdom, BN21 2UD
Sponsors and Collaborators
Guy Lloyd
Investigators
Principal Investigator: Guy W Lloyd, MD Eastbourne General Hospital
  More Information

No publications provided

Responsible Party: Guy Lloyd, Consultant Cardiologist, Eastbourne General Hospital
ClinicalTrials.gov Identifier: NCT01545102     History of Changes
Other Study ID Numbers: TN11-26
Study First Received: February 29, 2012
Last Updated: March 6, 2012
Health Authority: United Kingdom: National Health Service
United Kingdom: Research Ethics Committee

Additional relevant MeSH terms:
Heart Failure
Heart Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on September 16, 2014